Premium
Phototherapy for cutaneous T‐cell lymphoma
Author(s) -
Baron Elma D.,
Stevens Seth R.
Publication year - 2003
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1396-0296.2003.01642.x
Subject(s) - medicine , dermatology , psoralen , puva therapy , cutaneous t cell lymphoma , ultraviolet therapy , mycosis fungoides , adverse effect , lymphoma , ultraviolet b , phototoxicity , psoriasis , immunology , dna , genetics , biology , biochemistry , chemistry , in vitro
Phototherapy has been utilized for decades in the treatment of various dermatologic conditions, including cutaneous T‐cell lymphoma (CTCL). Currently, a number of light sources are available, and selection of the specific modality is based on a number of factors, the most important of which is disease stage. The efficacy of broadband ultraviolet B (UVB) is limited to the patch stage, while psoralen and ultraviolet A (PUVA) is capable of clearing plaques and, sometimes, early tumors. Narrowband UVB is also effective for early stages and has practical advantages over PUVA, but more studies are needed to more fully evaluate its role in CTCL. Long‐wave ultraviolet A (UVA1) has likewise shown efficacy, supported by findings of apoptosis induction in UVA1‐treated cells. Long‐term remissions have been reported for PUVA, but in the majority of cases, maintenance therapy was necessary. Although beneficial as monotherapy for early stages of the disease, phototherapy is also a useful adjunct to other modalities such as interferons, retinoids and electron beam therapy. Studies are ongoing to refine protocols for combination therapy, with the goal of improving efficacy, while minimizing adverse effects.